186 related articles for article (PubMed ID: 37153561)
1. Immunochemotherapy achieved a complete response for metastatic adenocarcinoma of unknown primary based on gene expression profiling: a case report and review of the literature.
Sheng J; Pan H; Han W
Front Immunol; 2023; 14():1181444. PubMed ID: 37153561
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Successful Immunotherapy Improved the Prognosis of the Unfavorable Subset of Cancer of Unknown Primary.
Mei J; Wang H; Fan H; Ding J; Xu J
Front Immunol; 2022; 13():900119. PubMed ID: 35812375
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment using immunotherapy in combination with chemotherapy for metastatic squamous cell carcinoma of unknown primary origin with bulky abdominal mass: A case report.
Zhang M; Zhao M; Jin LF; Shen WZ
Medicine (Baltimore); 2021 Dec; 100(48):e28074. PubMed ID: 35049231
[TBL] [Abstract][Full Text] [Related]
4. Pan-cancer landscape of
Kelly AD; Murugesan K; Kuang Z; Montesion M; Ross JS; Albacker LA; Huang RSP; Lin DI; Demirci U; Creeden J
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815356
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immune profiling for cancer of unknown primary site.
Haratani K; Hayashi H; Takahama T; Nakamura Y; Tomida S; Yoshida T; Chiba Y; Sawada T; Sakai K; Fujita Y; Togashi Y; Tanizaki J; Kawakami H; Ito A; Nishio K; Nakagawa K
J Immunother Cancer; 2019 Sep; 7(1):251. PubMed ID: 31519206
[TBL] [Abstract][Full Text] [Related]
6. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
[TBL] [Abstract][Full Text] [Related]
7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
8. Cancer of unknown primary with EGFR mutation successfully treated with targeted therapy directed by clinical next-generation sequencing: a case report.
Mitani Y; Kanai M; Kou T; Kataoka S; Doi K; Matsubara J; Ohashi S; Matsumoto S; Muto M
BMC Cancer; 2020 Dec; 20(1):1177. PubMed ID: 33267781
[TBL] [Abstract][Full Text] [Related]
9. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.
Posner A; Sivakumaran T; Pattison A; Etemadmoghadam D; Thio N; Wood C; Fisher K; Webb S; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Fellowes A; Fox SB; Hicks RJ; Schofield P; Bowtell D; Prall OWJ; Tothill RW; Mileshkin L
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720497
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report.
Kamada T; Ishiguro H; Okada S; Takeuchi H; Takahashi J; Nakashima K; Nakaseko Y; Suzuki N; Ohdaira H; Suzuki Y
Ann Med Surg (Lond); 2020 Dec; 60():31-35. PubMed ID: 33101670
[TBL] [Abstract][Full Text] [Related]
12. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
13. Case Report: Molecular Profiling Assists in the Diagnosis and Treatment of Cancer of Unknown Primary.
Yu B; Wang Q; Liu X; Hu S; Zhou L; Xu Q; Sun Y; Hu X; Luo Z; Zhang X
Front Oncol; 2022; 12():723140. PubMed ID: 35433426
[TBL] [Abstract][Full Text] [Related]
14. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases.
Huang RSP; Haberberger J; Severson E; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Williams E; Elvin J; Vergilio JA; Killian JK; Lin DI; Tse J; Hiemenz M; Owens C; Danziger N; Hegde PS; Venstrom J; Alexander B; Ross JS; Ramkissoon SH
Mod Pathol; 2021 Feb; 34(2):252-263. PubMed ID: 32884129
[TBL] [Abstract][Full Text] [Related]
15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
[TBL] [Abstract][Full Text] [Related]
17. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
18. NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma - a case report and review of the literature.
Nuytemans L; Sys G; Creytens D; Lapeire L
Acta Clin Belg; 2021 Apr; 76(2):162-167. PubMed ID: 31635553
[No Abstract] [Full Text] [Related]
19. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
[TBL] [Abstract][Full Text] [Related]
20. Dynamic changes in pathology and PD-L1 expression in a patient with metastatic lung adenocarcinoma who received pembrolizumab therapy followed by two salvage surgeries two years later: A case report.
Hong G; Park HS; Yeo MK; Lee D; Chung C
Thorac Cancer; 2023 Aug; 14(23):2320-2324. PubMed ID: 37416998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]